StockData
Vogenx, Inc. logo

Vogenx, Inc. (VOGX) stock

VOGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$13.48−0.90 (-6.26%)

Close on Nov 17, 2026Market cap $200.25MP/E –Yield –

Vogenx r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$156.79K–
Q2 FY2025Jun 30, 2025$136.39K–

More Vogenx figures

See a number that looks wrong?